Bioteque (4107) Q1 2025 earnings summary

Executive summary

• Operating revenue for Q1 2025 was NT$518.6 million, up 4.5% year-over-year from NT$496.3 million in Q1 2024.

• Net income for Q1 2025 reached NT$134.5 million, a 7% increase from NT$125.7 million in Q1 2024.

• Gross margin improved to 43% from 41% year-over-year.

• Comprehensive income for Q1 2025 was NT$142.4 million, including NT$7.9 million in foreign currency translation gains.

Financial highlights

• Operating costs were NT$293.9 million (57% of revenue), nearly flat year-over-year.

• Operating expenses totaled NT$65.6 million (12% of revenue), slightly up from NT$64.7 million.

• Basic and diluted EPS for Q1 2025 were NT$1.94 and NT$1.93, respectively, compared to NT$1.81 for both in Q1 2024.

• Cash and cash equivalents at quarter-end were NT$1,235.8 million, down from NT$1,451.9 million a year earlier.

• Net cash from operating activities was NT$213.8 million, up from NT$175.9 million year-over-year.

Outlook and guidance

• Management expects no significant impact from new IFRS standards effective in 2026 and 2027.

• No seasonality or cyclicality factors are expected to affect operations.